Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma : the IFM KRd final results
© 2021 by The American Society of Hematology..
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In this phase 2 study, patients received eight 28-day cycles of carfilzomib (K) 20/36 mg/m2 (days 1-2, 8-9, 15-16), lenalidomide (R) 25 mg (days 1-21), and dexamethasone (d) 20 mg (days 1-2, 8-9, 15-16, 22-23). All patients proceeded to transplant after 4 cycles and received 1 year of lenalidomide maintenance (10 mg, days 1-21). The primary objective was stringent complete response at the completion of consolidation. Overall, 48 patients were screened and 46 enrolled; 21% had adverse cytogenetics. Among 42 evaluable patients after consolidation, 26 were in stringent complete response (CR; 61.9%), 27 were at least in CR (64.3%): 92.6% had undetectable minimal residual disease according to flow cytometry (≥2.5 × 10-5) and 63.0% according to next-generation sequencing (10-6). Median time to CR was 10.6 months. According to multiparametric flow cytometry and next-generation sequencing, 69.0% and 66.7% of patients, respectively, had undetectable minimal residual disease at some point. With a median follow-up of 60.5 months, 21 patients progressed, and 10 died (7 of multiple myeloma). Median progression-free survival was 56.4 months. There were no KRd-related deaths. Four patients discontinued the program due to toxicities; 56 serious adverse events were reported in 31 patients, including 8 cardiovascular events (2 heart failures, 5 pulmonary embolisms or deep vein thrombosis). Common grade 3/4 adverse events were hematologic (74%) and infectious (22%). In summary, 8 cycles of KRd produce fast and deep responses in transplant-eligible patients with newly diagnosed multiple myeloma. The safety profile is acceptable, but cardiovascular adverse events should be closely monitored. This clinical trial is registered at www.clinicaltrials.gov as #NCT02405364.
| Errataetall: |
CommentIn: Blood. 2021 Jul 15;138(2):105-106. - PMID 34264276 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:138 |
|---|---|
| Enthalten in: |
Blood - 138(2021), 2 vom: 15. Juli, Seite 113-121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Roussel, Murielle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
72X6E3J5AR |
|---|
| Anmerkungen: |
Date Completed 30.07.2021 Date Revised 30.07.2021 published: Print ClinicalTrials.gov: NCT02405364 CommentIn: Blood. 2021 Jul 15;138(2):105-106. - PMID 34264276 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2021010744 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323823920 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323823920 | ||
| 003 | DE-627 | ||
| 005 | 20231225185016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2021010744 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323823920 | ||
| 035 | |a (NLM)33827114 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Roussel, Murielle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma |b the IFM KRd final results |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.07.2021 | ||
| 500 | |a Date Revised 30.07.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02405364 | ||
| 500 | |a CommentIn: Blood. 2021 Jul 15;138(2):105-106. - PMID 34264276 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 by The American Society of Hematology. | ||
| 520 | |a Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In this phase 2 study, patients received eight 28-day cycles of carfilzomib (K) 20/36 mg/m2 (days 1-2, 8-9, 15-16), lenalidomide (R) 25 mg (days 1-21), and dexamethasone (d) 20 mg (days 1-2, 8-9, 15-16, 22-23). All patients proceeded to transplant after 4 cycles and received 1 year of lenalidomide maintenance (10 mg, days 1-21). The primary objective was stringent complete response at the completion of consolidation. Overall, 48 patients were screened and 46 enrolled; 21% had adverse cytogenetics. Among 42 evaluable patients after consolidation, 26 were in stringent complete response (CR; 61.9%), 27 were at least in CR (64.3%): 92.6% had undetectable minimal residual disease according to flow cytometry (≥2.5 × 10-5) and 63.0% according to next-generation sequencing (10-6). Median time to CR was 10.6 months. According to multiparametric flow cytometry and next-generation sequencing, 69.0% and 66.7% of patients, respectively, had undetectable minimal residual disease at some point. With a median follow-up of 60.5 months, 21 patients progressed, and 10 died (7 of multiple myeloma). Median progression-free survival was 56.4 months. There were no KRd-related deaths. Four patients discontinued the program due to toxicities; 56 serious adverse events were reported in 31 patients, including 8 cardiovascular events (2 heart failures, 5 pulmonary embolisms or deep vein thrombosis). Common grade 3/4 adverse events were hematologic (74%) and infectious (22%). In summary, 8 cycles of KRd produce fast and deep responses in transplant-eligible patients with newly diagnosed multiple myeloma. The safety profile is acceptable, but cardiovascular adverse events should be closely monitored. This clinical trial is registered at www.clinicaltrials.gov as #NCT02405364 | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Oligopeptides |2 NLM | |
| 650 | 7 | |a carfilzomib |2 NLM | |
| 650 | 7 | |a 72X6E3J5AR |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Lauwers-Cances, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Wuilleme, Soraya |e verfasserin |4 aut | |
| 700 | 1 | |a Belhadj, Karim |e verfasserin |4 aut | |
| 700 | 1 | |a Manier, Salomon |e verfasserin |4 aut | |
| 700 | 1 | |a Garderet, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Escoffre-Barbe, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Mariette, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Benboubker, Lotfi |e verfasserin |4 aut | |
| 700 | 1 | |a Caillot, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Sonntag, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Touzeau, Cyrille |e verfasserin |4 aut | |
| 700 | 1 | |a Dupuis, Jehan |e verfasserin |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Leleu, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Facon, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Hébraud, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Corre, Jill |e verfasserin |4 aut | |
| 700 | 1 | |a Attal, Michel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 138(2021), 2 vom: 15. Juli, Seite 113-121 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:138 |g year:2021 |g number:2 |g day:15 |g month:07 |g pages:113-121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2021010744 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 138 |j 2021 |e 2 |b 15 |c 07 |h 113-121 | ||